L&G Pharma Breakthrough UCITS ETF
ETF (UCITS compliant)
L&G Pharma Breakthrough UCITS ETF
USD Accumulating ETF Class
ISINIE00BF0H7608
Price
TER0.49%
ISINIE00BF0H7608
Price
TER0.49%
Fund aim
The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").
Fund snapshot
- Long-term allocation
Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives
- High growth potential
Aims to capture the future growth opportunity in orphan drugs
- Leveraging industry expertise
An index tracking investment strategy that is supported by a team of pharmaceutical experts
- Does it have a sustainable objective?
The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.
Fund facts
Fund size | $22.9m |
Base currency | USD |
Fund launch date | 15 Dec 2017 |
Domicile | Ireland |
Share class launch | 23 Jan 2018 |
Replication method | Physical - backed by equities |
ISA eligible | Yes |
SIPP eligible | Yes |
UK Fund Reporting status | Yes |
Benchmark
Solactive Pharma Breakthrough Value Index
Index description
Solactive Pharma Breakthrough Value Index Net TR USD
The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently “liquid” (a measure of how actively its shares are traded on a daily basis).
The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.
Index data
Provider | Solactive |
Bloomberg code | SOLBIOT |
Reuters code | .SOLBIOT |
Type | Net Total Return |
Website | Go to website |
Performance
Portfolio breakdown
As at 29 Feb 2024
Top 10 constituents | 39.1% |
---|---|
Rest of Index | 60.9% |
No. of constituents in Index | 32 |
---|
Top 10 constituents (%)
Chugai Pharmaceutical | 4.6 |
Swedish Orphan Biovitrum | 4.4 |
Innovent Biologics | 4.2 |
Vertex Pharmaceuticals | 4.1 |
Ionis Pharmaceuticals | 3.9 |
Kyowa Kirin | 3.8 |
Sino Biopharmaceutical | 3.6 |
Sarepta Therapeutics | 3.6 |
Royalty Pharma | 3.5 |
United Therapeutics | 3.4 |
Sector (%)
Health Care | 100.0 |
Top 10 constituents | 39.1% |
---|---|
Rest of Index | 60.9% |
No. of constituents in Index | 32 |
---|
Top 10 constituents (%)
Chugai Pharmaceutical | 4.6 |
Swedish Orphan Biovitrum | 4.4 |
Innovent Biologics | 4.2 |
Vertex Pharmaceuticals | 4.1 |
Ionis Pharmaceuticals | 3.9 |
Kyowa Kirin | 3.8 |
Sino Biopharmaceutical | 3.6 |
Sarepta Therapeutics | 3.6 |
Royalty Pharma | 3.5 |
United Therapeutics | 3.4 |
Sector (%)
Health Care | 100.0 |
Currency (%)
USD | 54.8 |
JPY | 18.8 |
HKD | 10.5 |
EUR | 9.0 |
SEK | 4.4 |
DKK | 2.5 |
Country (%)
United States | 48.4 |
Japan | 18.8 |
Cayman Islands | 10.5 |
Sweden | 4.4 |
United Kingdom | 3.5 |
Netherlands | 3.0 |
France | 3.0 |
Spain | 3.0 |
Ireland | 2.9 |
Denmark | 2.5 |
All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.
Fund managers
LGIM Index Fund Management Team
The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.
Sustainability
SFDR categorisation
Article 9The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The Fund follows the following sustainability-related investment strategy by tracking the Index that applies:
Literature
Document type
Prices
Pricing information
Price time | 16:00 EST (NY) |
Currency | USD |
Listings and codes
Listings
Exchange | Currency | Ticker | ISIN | Bloomberg | Reuters | Listing date | Trading hours (local) |
---|---|---|---|---|---|---|---|
London Stock Exchange | GBP | BIGT | IE00BF0H7608 | BIGT LN | BIGT.L | 23/01/2018 | 08:00 - 16:30 |
London Stock Exchange | USD | BIOT | IE00BF0H7608 | BIOT LN | GEBIOT.L | 23/01/2018 | 08:00 - 16:30 |
Borsa Italiana | EUR | BIOT | IE00BF0H7608 | BIOT IM | ECBIOT.MI | 23/02/2018 | 09:00 - 17:30 |
Deutsche Börse Xetra | EUR | ETLI | IE00BF0H7608 | ETLI GY | ETLI.DE | 06/02/2018 | 09:00 - 17:30 |
Euronext Amsterdam | EUR | BIOT | IE00BF0H7608 | BIOT NA | GOBIOT.AS | 01/02/2018 | 09:00 - 17:30 |
SIX Swiss Exchange | CHF | BIOT | IE00BF0H7608 | BIOT SW | BIOTC.S | 05/06/2020 | 09:00 - 17:30 |
Codes
ISIN | IE00BF0H7608 |
SEDOL | BF0H760 |
Bloomberg | BIOT |
MEX | - |
Dealing information
Issuer | Legal & General UCITS ETF Plc |
Depositary and Trustee | The Bank of New York Mellon SA/NV, Dublin Branch |
Securities regulator | Central Bank of Ireland |
Country registration
This share class is registered for sale in the following countries: